
An inhalation device to facilitate smoking cessation is shown to be effective
Qnovia presented data from the first phase of studies of the effectiveness of the QN-01 device with the participation of volunteers.
Qnovia has submitted the study data to the US Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA).
A study involving 12 smoking volunteers assessed the delivery of nicotine at three different dosages using the QN-01 device. Participants took a short smoking break before taking the study. Using the QN-01 device was better at delivering nicotine into the bloodstream compared to existing nicotine replacement therapies.
According to Qnovia CEO Brian Quigley, quickly delivering a sufficient dose of nicotine can solve the problem of withdrawal symptoms when quitting smoking: “One of the reasons why quitting smoking is so difficult is the sharp jump in nicotine levels in the blood that cigarettes cause in a matter of seconds. The problem with existing nicotine replacement therapies is that they do not deliver nicotine at a high enough rate or concentration to effectively relieve withdrawal symptoms. Unfortunately, this leads to smoking relapse, and as a result there is a significant need for new methods of overcoming tobacco addiction.”
In addition, Quigley emphasized the safety of the QN-01. According to him, the formation of an aerosol in the device does not occur due to heating, due to which toxic substances are not released.
It is planned that in the US the nicotine replacement therapy device will be prescribed by a doctor. In terms of its mechanism of action, the device is breath activated by the user and delivers precise doses effectively via inhalation while addressing cue induced relapse behavior. The device tracks and displays real-time dosing to help patients successfully follow a 12-week step down regimen. All of this data is easily accessible on the device, smartphone or both.
According to Qnovia, smoking remains the leading preventable cause of death and disease in the world. Every year, smoking is a direct or indirect cause of death for eight million people worldwide. Every year in the US and UK, about 34 million smokers try to overcome their nicotine addiction.
References:
- https://pharmvestnik.ru/content/news/Qnovia-predstavila-dannye-issledovaniya-ustroistva-dlya-otkaza-ot-kureniya.html
- https://www.businesswire.com/news/home/20231129757219/en/Qnovia-Inc.-announces-positive-results-from-first-in-human-pharmacokinetic-and-safety-study-of-lead-asset-QN-01-a-prescription-inhaled-smoking-cessation-therapy
- https://www.qnovia.com/nrt/